MARGENZA (Margetuximab-cmkb)
- Name: Margenza
- Generic Name: Margetuximab-cmkb
- Dosage Form & Strength: 250mg/10mL (25mg/mL) Single-dose Vial
- Manufactured: MacroGenics Inc.
Medical Uses
Margenza is a HER2/neu receptor antagonist used, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2 +Ve breast cancer who have previously received 2 or more anti-HER2 regimens, at least 1 of which was for metastatic disease.
Recommended Dosage: The recommended dose of Margenza (Margetuximab) is 15 mg/kg, administered as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. Administer margetuximab dosage as an intravenous infusion at 15 mg/kg over 120 minutes for the initial dose, then over a minimum of 30 minutes every 3 weeks for all subsequent doses. On those days when both margetuximab and chemotherapy are to be administered, margetuximab may be administered promptly after the completion of chemotherapy.
Warning & Precautions
- The margetuximab breast cancer medicine has not been studied in populations with a pretreatment LVEF value of <50%, a prior history of myocardial infarction or unstable angina within 6 months, or congestive heart failure NYHA class II-IV.
- Permanently discontinue therapy with margenza drug in case LVEF decline persists greater than 8 weeks, or dosing is interrupted more than 3 times because of the LVEF decline.
- Evaluate cardiac function within 4 weeks before and every 3 months during and upon completion of treatment. Conduct thorough cardiac evaluation, including history, physical assessment, and determination of LVEF by echocardiogram or MUGA scan.
- Monitor cardiac function every 4 weeks in case margenza 25 mg is withheld for significant left ventricular cardiac dysfunction.
- Margetuximab can be responsible for causing fetal harm if administered to a pregnant woman. Verify the pregnancy status prior to initiation of therapy..
- Margetuximab may cause IRRs. Signs/symptoms may include chills, arthralgia, fever, dizziness, cough, fatigue, nausea, vomiting, tachycardia, headache, diaphoresis, hypotension, pruritus, rash, urticaria, and dyspnea.
- Monitor patients while on and following margetuximab infusion. Have medicines and emergency equipment in order to treat IRRs available for immediate use.
Documentation & Availability
What documents are required to import MARGENZA to India?
MARGENZA (Margetuximab cmkb) can be imported by patients or government hospitals on the name of the patients only.
The following documentation are needed to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of the respective country).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is MARGENZA available in India?
MARGENZA is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
S S Healthcare (S S Healthcare) helps import cancer medicines on the named patient supply (NPS). S S Healthcare is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
MARGENZA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
S S Healthcare (S S Healthcare) can facilitate the supply of MARGENZA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Contact +91-7575883015 | Toll-Free No: +91-7575883015 or write us at sshealthcare1012@gmail.com
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirementsc
Sourcing & Delivery
S S Healthcare is able to source MARGENZA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. S S Healthcare offers its customers worldwide access to the best available treatment.
S S Healthcare is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Margenza®?
Margetuximab is Generic Name for the trade name drug Margenza®.
What is the Manufacturer Name of Margenza®?
Margenza® is manufactured by MacroGenics Inc.
Is Margenza® approved by the FDA?
Yes, Margenza® is approved by the FDA. Date of approval: December 16, 2020.
What is the dosage and form of Margenza® available?
Margenza® is available as injection: 250 mg/10 mL (25 mg/mL) in a single-dose vial for intravenous infusion.
How is Margenza® given?
The proposed dosage of Margenza® is given as intravenous infusion only.
What are the most common side effects due to Margenza®?
Most common side effects due to Margenza® in combination with chemotherapy include: diarrhea, fatigue, nausea, pyrexia, vomiting, constipation, cough, headache, alopecia, abdominal pain, peripheral neuropathy, decreased appetite, dyspnea, infusion-related reactions, and extremity pain.
What are the storage conditions of Margenza®?
Store the vials of this medicinal product at 2°C to 8°C (36°F to 46°F) in the original carton in order to protect from the light until time of use. Neither freeze, nor shake.
How much does Margenza® cost in India?
You can call or WhatsApp +91-7575883015 or send mail to sshealthcare1012@gmail.com to know the margenza cost in India.
What are the Highlights of prescribing information for Margenza®?
Click Here to download full margenza prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
